United Therapeutics Q2 Revenue Misses as Nebulized Tyvaso Slides 18%, But Pipeline Advances with Two Key Submissions
UTHR sits 67% above its 52-week low of $287.645.
Summary
United Therapeutics' Q2 revenue fell 2% to $783.3M as Nebulized Tyvaso sales dropped 18%, but the company submitted regulatory filings for two major pipeline drugs and completed a $1.5B buyback.
Key Events · Earnings and Guidance · UTHR
-
Q2 Revenue Miss Driven by Nebulized Tyvaso
Total revenue of $783.3M missed estimates, down 2% YoY. Nebulized Tyvaso sales fell 18% to $126.0M due to competition from Yutrepia and Winrevair. Tyvaso DPI grew 4% to $326.6M, partially offsetting the decline.
-
Pipeline Milestones: sNDA and NDA Submitted
Submitted an sNDA for Nebulized Tyvaso in IPF and an NDA for ralinepag extended-release tablets in PAH. Both address large markets — approximately 100,000 U.S. IPF patients and a PAH market where Uptravi generated over $1.5B in U.S. sales in 2025.
-
$1.5B Accelerated Share Repurchase Completed
Completed the $1.5B ASR, repurchasing 2.76M shares. $500M remains under the $2B authorization through March 2027. The buyback reduced diluted shares outstanding to 45.8M from 48.3M a year ago, boosting EPS.
-
Thymmune Therapeutics Acquired for Up to $300M
Acquired Thymmune on July 1, 2026 for $140M upfront plus up to $160M in milestones. The deal adds a preclinical thymic cell therapy platform targeting organ transplant tolerance and immunodeficiencies.
Analysis · UTHR · Life Sciences
A mixed quarter for United Therapeutics. Total revenue of $783.3 million fell 2% year-over-year, missing estimates, as Nebulized Tyvaso sales dropped 18% under intensifying competitive pressure from Liquidia's Yutrepia and Merck's Winrevair. Tyvaso DPI grew 4%, partially offsetting the decline. Despite the top-line miss, net income rose to $333 million from $309.5 million a year ago, helped by a lower tax rate. The company completed a $1.5 billion accelerated share repurchase, reducing the share count and boosting EPS. Critically, two major regulatory filings were submitted: an sNDA for Nebulized Tyvaso in idiopathic pulmonary fibrosis (IPF) and an NDA for ralinepag in pulmonary arterial hypertension (PAH). Both represent significant commercial opportunities. Also disclosed were a new trade secret lawsuit from Boehringer Ingelheim and the acquisition of Thymmune Therapeutics for up to $300 million. The results highlight a company in transition — legacy products face headwinds, but the pipeline is advancing toward potential blockbuster approvals.
At the time of this filing, UTHR was trading at $480.00 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $22B. The 52-week trading range was $287.65 to $609.35. This filing was assessed with neutral market sentiment and an importance score of 8 out of 10.